Cost–utility analysis of germline BRCA1/2 testing in women with high‑grade epithelial ovarian cancer in Spain
Materias Investigacion::Ciencias de la Salud::Oncología
BRCA1 gene
BRCA2 gene
Cancer screening test
Cost–utility analysis
Ovarian cancer
Quality-adjusted life years
Issue Date: 
Springer Science and Business Media LLC
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Moya‑Alarcón, C. (Carlota); González‑Domínguez, A. (Almudena); Simón, S. (Susana); et al. "Cost–utility analysis of germline BRCA1/2 testing in women with high‑grade epithelial ovarian cancer in Spain". Clinical and Translational Oncology. 21, 2019, 1076 - 1084
Purpose: Germline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC). The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain. Methods/patients: Incident HGEOC patients without family history of OC or BC who were gBRCA1/2m carriers and their relatives were simulated in a 50-year time horizon. The study compared two scenarios: BRCA1/2 testing vs no testing, using the perspective of the Spanish National Health Service. Cancer risk among gBRCA1/2m carriers was estimated based on their age and whether they had undergone risk-reducing surgeries. Direct healthcare costs and utilities of patients who developed EOC and BC were also included. A probabilistic sensitivity analysis (PSA) with 5 thousand simulations was developed considering ± 25% of the base-case value. Results: The BRCA1/2-testing scenario amounted to €13,437,897.43 while the no-testing scenario amounted to €12,053,291.17. It was estimated that the screening test improved the quality of life among the patients' relatives by 43.8 quality-adjusted life years (QALYs). The incremental cost-utility ratio (ICUR) was €31,621.33/QALY in the base case. The PSA showed that 89.12% of the simulations were below the €50,000/QALY threshold. Conclusion: Providing this screening test to HGEOC patients and their relatives is cost-effective and it allows one to identify a target population with high risk of cancer to provide effective prevention strategies.

Files in This Item:
1.33 MB
Adobe PDF

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.